Nektar Therapeutics Cost of Goods Sold (Deprecated 2018-01-31)
Nektar Therapeutics (NKTR) reported Cost of Goods Sold (Deprecated 2018-01-31) of $6.65 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-05-10
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $6.65M, a 8.40% increase year-over-year.
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $9.75M, a 47.68% increase year-over-year.
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $5.67M, a 19.32% decline year-over-year.
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $8.99M, a 16.62% increase year-over-year.
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $30.55M, a 1.10% increase from fiscal 2016.
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $30.21M, a 11.40% decline from fiscal 2015.
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $34.10M, a 19.52% increase from fiscal 2014.
- Nektar Therapeutics cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $28.53M, a 25.91% decline from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $6.65M 10-Q · filed 2018-05-10 | $16.40M derived: sum of 2 quarters · filed 2018-05-10 | $22.07M derived: sum of 3 quarters · filed 2018-05-10 | $31.06M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $9.75M 10-K · filed 2018-03-01 | $15.43M derived: sum of 2 quarters · filed 2018-03-01 | $24.42M derived: sum of 3 quarters · filed 2018-03-01 | $30.55M 10-K · filed 2018-03-01 |
| 2017-09-30 | $5.67M 10-K · filed 2018-03-01 | $14.66M derived: sum of 2 quarters · filed 2018-03-01 | $20.79M 10-Q · filed 2017-11-08 | $27.40M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | $8.99M 10-K · filed 2018-03-01 | $15.12M 10-Q · filed 2017-08-09 | $21.72M derived: sum of 3 quarters · filed 2018-05-10 | $28.76M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | $6.13M 10-Q · filed 2018-05-10 | $12.73M derived: sum of 2 quarters · filed 2018-05-10 | $19.77M derived: sum of 3 quarters · filed 2018-05-10 | $27.48M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $6.60M 10-K · filed 2018-03-01 | $13.64M derived: sum of 2 quarters · filed 2018-03-01 | $21.34M derived: sum of 3 quarters · filed 2018-03-01 | $30.21M 10-K · filed 2018-03-01 |
| 2016-09-30 | $7.03M 10-K · filed 2018-03-01 | $14.74M derived: sum of 2 quarters · filed 2018-03-01 | $23.61M 10-Q · filed 2017-11-08 | $31.98M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $7.71M 10-K · filed 2018-03-01 | $16.58M 10-Q · filed 2017-08-09 | $24.94M derived: sum of 3 quarters · filed 2018-03-01 | $31.70M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $8.87M 10-K · filed 2018-03-01 | $17.23M derived: sum of 2 quarters · filed 2018-03-01 | $23.99M derived: sum of 3 quarters · filed 2018-03-01 | $34.53M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $8.36M 10-K · filed 2017-03-01 | $15.12M derived: sum of 2 quarters · filed 2017-03-01 | $25.66M derived: sum of 3 quarters · filed 2017-03-01 | $34.10M 10-K · filed 2018-03-01 |
| 2015-09-30 | $6.76M 10-K · filed 2017-03-01 | $17.29M derived: sum of 2 quarters · filed 2017-03-01 | $25.74M 10-Q · filed 2016-11-04 | $32.04M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $10.53M 10-K · filed 2017-03-01 | $18.98M 10-Q · filed 2016-08-04 | $25.28M derived: sum of 3 quarters · filed 2017-03-01 | $34.50M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $8.44M 10-K · filed 2017-03-01 | $14.74M derived: sum of 2 quarters · filed 2017-03-01 | $23.96M derived: sum of 3 quarters · filed 2017-03-01 | $29.07M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $6.30M 10-K · filed 2016-02-29 | $15.52M derived: sum of 2 quarters · filed 2016-02-29 | $20.63M derived: sum of 3 quarters · filed 2016-02-29 | $28.53M 10-K · filed 2017-03-01 |
| 2014-09-30 | $9.22M 10-K · filed 2016-02-29 | $14.33M derived: sum of 2 quarters · filed 2016-02-29 | $22.23M 10-Q · filed 2015-11-06 | $31.20M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $5.11M 10-K · filed 2016-02-29 | $13.02M 10-Q · filed 2015-08-06 | $21.98M derived: sum of 3 quarters · filed 2016-02-29 | $34.85M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $7.91M 10-K · filed 2016-02-29 | $16.87M derived: sum of 2 quarters · filed 2016-02-29 | $29.74M derived: sum of 3 quarters · filed 2016-02-29 | $34.76M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $8.96M 10-K · filed 2015-02-26 | $21.84M derived: sum of 2 quarters · filed 2015-02-26 | $26.85M derived: sum of 3 quarters · filed 2015-02-26 | $38.51M 10-K · filed 2016-02-29 |
| 2013-09-30 | $12.88M 10-K · filed 2015-02-26 | $17.89M derived: sum of 2 quarters · filed 2015-02-26 | $29.55M 10-Q · filed 2014-11-07 | $36.84M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $5.01M 10-K · filed 2015-02-26 | $16.67M 10-Q · filed 2014-08-01 | $23.96M derived: sum of 3 quarters · filed 2015-02-26 | $31.19M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $11.66M 10-K · filed 2015-02-26 | $18.95M derived: sum of 2 quarters · filed 2015-02-26 | $26.18M derived: sum of 3 quarters · filed 2015-02-26 | $33.38M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $7.29M 10-K · filed 2014-02-27 | $14.52M derived: sum of 2 quarters · filed 2014-02-27 | $21.72M derived: sum of 3 quarters · filed 2014-02-27 | $30.43M 10-K · filed 2015-02-26 |
| 2012-09-30 | $7.23M 10-K · filed 2014-02-27 | $14.43M derived: sum of 2 quarters · filed 2014-02-27 | $23.14M 10-Q · filed 2013-11-07 | $28.59M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $7.20M 10-K · filed 2014-02-27 | $15.91M 10-Q · filed 2013-08-09 | $21.36M derived: sum of 3 quarters · filed 2014-02-27 | $26.40M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $8.71M 10-K · filed 2014-02-27 | $14.16M derived: sum of 2 quarters · filed 2014-02-27 | $19.20M derived: sum of 3 quarters · filed 2014-02-27 | $27.34M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $5.45M 10-K · filed 2013-03-01 | $10.49M derived: sum of 2 quarters · filed 2013-03-01 | $18.63M derived: sum of 3 quarters · filed 2013-03-01 | $21.89M 10-K · filed 2014-02-27 |
| 2011-09-30 | $5.04M 10-K · filed 2013-03-01 | $13.18M derived: sum of 2 quarters · filed 2013-03-01 | $16.44M 10-Q · filed 2012-11-09 | $26.68M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $8.14M 10-K · filed 2013-03-01 | $11.40M 10-Q · filed 2012-08-09 | $21.64M derived: sum of 3 quarters · filed 2013-03-01 | $27.89M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $3.26M 10-K · filed 2013-03-01 | $13.50M derived: sum of 2 quarters · filed 2013-03-01 | $19.75M derived: sum of 3 quarters · filed 2013-03-01 | $24.63M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $10.24M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $16.48M derived: sum of 2 quarters · filed 2013-03-01 | $21.37M derived: sum of 3 quarters · filed 2013-03-01 | $25.67M 10-K · filed 2013-03-01 |
| 2010-09-30 | $6.25M 10-Q · filed 2011-11-04 | $11.13M derived: sum of 2 quarters · filed 2011-11-04 | $15.43M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $4.89M 10-Q · filed 2011-08-05 | $9.19M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $4.30M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | $30.95M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |